Амілін (Cagrilintide) (Амілін)
buy in Ukraine
Amylin analog — a new pathway for appetite control
Long-acting amylin hormone analog. Novo Nordisk molecule, PeptoLabs product. Separate from GLP-1 mechanism — combines with Mounjaro, Ozempic, Biopatid, Retatrutide. 10/20 mg pens.
Виробник: PeptoLabs Amilin (10 мг або 20 мг pre-mixed pen). Стандартна титрація CagriSema (Novo Nordisk Phase 3): тижні 1–4 — 0.25 мг/тиждень; тижні 5–8 — 0.5 мг/тиждень; тижні 9–12 — 1.0 мг/тиждень; тижні 13–16 — 1.7 мг/тиждень; з 17 тижня — підтримуюча 2.4 мг/тиждень. Розрахунок ручок: 16-тижневий вступний курс ≈ 27 мг → 3 ручки 10 мг або 1.5 ручки 20 мг. Підтримка на 2.4 мг/тиждень: ручка 20 мг — на 8–9 тижнів, ручка 10 мг — на 4 тижні. Курс довгостроковий — мінімум 6 місяців для значущого зниження ваги. Клінічні дослідження REDEFINE-1/2 — 68 тижнів. Можна комбінувати з GLP-1 (Mounjaro, Ozempic) для синергії — у комбінації ефект сильніший на 30–50%.
Free specialist consultation
Benefits
- ✓Separate from GLP-1 mechanism — synergy when combined with Ozempic/Mounjaro
- ✓–22.7% weight loss in CagriSema (REDEFINE-1, 68 weeks) — best result among incretin therapies
- ✓–10.8% in monotherapy over 26 weeks (Phase 2, Lancet 2021)
- ✓In T2D on metformin: –15.6% weight, –2.2% HbA1c combined with semaglutide
- ✓Does NOT cause hypoglycemia (unlike insulin and sulfonylureas)
- ✓Gradual 16-week titration — smooth buildup, minimal side effects
- ✓Convenient weekly dosing — half-life ~7 days
- ✓Cardiovascular risk reduction in T2D (secondary endpoint REDEFINE-2)
- ✓Alternative/addition for patients plateauing on GLP-1 monotherapy
Who it's for
- ✔️Weight plateau on GLP-1 (Ozempic/Mounjaro) — adding cagrilintide gives +6–10% reduction
- ✔️Patients who don't tolerate high GLP-1 doses — lower dose + cagrilintide instead of dose increase
- ✔️T2D on metformin — better glycemic and weight control than semaglutide-mono
- ✔️Biohackers / advanced users seeking maximum CagriSema protocol effect
- ✔️Post-surgical weight maintenance (bariatric) — adjuvant against recidivism
- ✔️Those wanting SEPARATE appetite control mechanism without duplicating GLP-1
How to take
Standard 16-week titration (Novo Nordisk Phase 3 CagriSema):
• Weeks 1–4: 0.25 mg subcutaneous once weekly.
• Weeks 5–8: 0.5 mg subcutaneous once weekly.
• Weeks 9–12: 1.0 mg subcutaneous once weekly.
• Weeks 13–16: 1.7 mg subcutaneous once weekly.
• Week 17+: 2.4 mg subcutaneous once weekly (maintenance).
Maximum dose in clinical studies: 4.5 mg/week (Phase 2 mono); in CagriSema — 2.4 mg/week.
Administration: subcutaneous in abdomen, thigh or arm. One day per week — e.g., "Cagri-Sunday". Can inject any time of day regardless of meals. Rotate injection sites. PeptoLabs pen — programmable, set mg.
Combination with GLP-1 (CagriSema protocol DOZA):
• Usually inject on different days (Mounjaro Monday, Cagri Friday) — to better assess tolerability.
• When combining with GLP-1, titration may be slower to avoid cumulative GI side effects.
• Combination start — only after stabilization on GLP-1 (2.4 mg or 5 mg).
Storage: 2–8°C (refrigerator). Do not freeze. Outside cold storage — no longer than 4 hours (during travel in thermal bag).
Before starting — mandatory DOZA specialist consultation (assessment of goals, risks, protocol).
Full description
Cagrilintide is a long-acting analog of human amylin hormone, developed by Novo Nordisk as a key component of the CagriSema project (cagrilintide + semaglutide). The molecule is a modified amylin with added fatty acid (like semaglutide), extending half-life from 12 minutes (native amylin) to ~7 days — convenient weekly dosing.
Amylin is the second hormone of pancreatic β-cells (alongside insulin), released in response to food intake. It regulates satiation through action on the area postrema (brain area outside blood-brain barrier) and nucleus tractus solitarius (NTS). This is a SEPARATE pathway from GLP-1 for appetite control — therefore cagrilintide synergistically combines with semaglutide, tirzepatide, retatrutide.
Clinical results:
• Phase 2 monotherapy (Lancet 2021, n=706, 26 weeks): –10.8% weight loss at 4.5 mg/week dose.
• REDEFINE-1 (NEJM 2024, n=3417, 68 weeks): CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) → –22.7% weight loss (ozempic 2.4 mg → –16.1%).
• REDEFINE-2 (n=1206, T2D): CagriSema → –13.7% weight loss, –1.8% HbA1c — better result than semaglutide-mono.
• Phase 2 T2D on metformin: cagrilintide 1.2 mg + semaglutide 1.2 mg → –15.6% weight loss, –2.2% HbA1c.
Manufacturer: PeptoLabs Amilin (10 mg or 20 mg pre-mixed pen). Storage: 2–8°C, do not freeze. Product not yet FDA/EMA approved (CagriSema approval expected 2026–2027 — Phase 3 successfully completed). Available at DOZA as research-grade medication for patients not achieving goals on GLP-1 monotherapy.
Mechanism of action
Cagrilintide is modified amylin: natural 37 amino acid sequence + conjugated C20-fatty acid via linker (like semaglutide) → plasma albumin binding → half-life extension from 12 min to ~7 days → weekly dosing. Mechanism of action: 1) Activation of amylin receptors (AMY1, AMY2, AMY3 — heterodimers of calcitonin receptor with RAMP1/2/3) in area postrema and NTS → appetite suppression and enhanced satiation. 2) Slows gastric emptying (synergy with GLP-1 in CagriSema). 3) Suppresses postprandial glucagon secretion → ↓post-meal hyperglycemia. 4) Separate from GLP-1 receptor pathway → synergy when combined (CagriSema, cagrilintide+tirzepatide). 5) Unlike pramlintide (short-acting amylin, FDA 2005) doesn't require 3-times daily dosing — weekly format improves compliance. 6) Does NOT cause hypoglycemia when used without insulin — amylin signaling is physiological.
Side effects & contraindications
Cagrilintide is well tolerated. Side effect profile similar to GLP-1 but milder (especially with proper 16-week titration).
Common (10–20%, mainly during titration start):
• Nausea — 15–25% at start, resolves within 5–7 days of adaptation.
• Decreased appetite — desired therapeutic effect.
• Constipation or diarrhea — 10–15%.
• Delayed gastric emptying, heaviness after meals — 8–12%.
Less common (3–5%):
• Injection site reaction (redness, itching) — mild, temporary.
• Headache — rare.
• Fatigue first 1–2 weeks.
• Cholelithiasis (gallstones) — like GLP-1, due to rapid weight loss.
Serious (rare):
• Severe gastroparesis — in patients with existing diabetic gastroparesis.
• Allergic reactions — rare.
• Theoretical risk of medullary thyroid cancer (MTC) — like GLP-1; studies ongoing.
Contraindications:
• Personal or family history of medullary thyroid cancer (MTC).
• Multiple endocrine neoplasia type 2 (MEN-2).
• Active diabetic gastroparesis.
• History of intestinal obstruction.
• Active pancreatitis.
• Severe gastroesophageal reflux with esophagitis.
• Pregnancy and lactation.
• Allergy to medication components.
• Severe renal insufficiency (eGFR <30) — limited data.
At DOZA before starting — history assessment and optional baseline labs (TSH, lipase, eGFR). Specialist consultation — mandatory.
Scientific research
📄Cagrilintide — об'єкт активної клінічної програми Novo Nordisk з 2018 року. Ключові дослідження: 1) Phase 1b mono (Diabetes Care 2021) — досліджено 0.16–4.5 мг/тиждень × 26 тижнів, dose-dependent зниження ваги до –10.8%. 2) Phase 2 ЦД2 + метформін — cagrilintide 1.2 + semaglutide 1.2 = –15.6% ваги, –2.2% HbA1c (vs semaglutide 2.4 моно: –5.1% / –1.8%). 3) REDEFINE-1 (NEJM 2024, n=3417, 68 тижнів) — CagriSema (cagrilintide 2.4 + semaglutide 2.4) → –22.7% ваги (ozempic 2.4 → –16.1%, cagrilintide 2.4 mono → –11.8%, placebo → –2.3%). 4) REDEFINE-2 (n=1206, ЦД2) — CagriSema → –13.7% ваги, –1.8% HbA1c. 5) Phase 3 CagriSema очікує одобрення FDA 2026–2027 як перший dual-agonist amylin+GLP-1 препарат. 6) Тривають Phase 3 для серцево-судинних кінцевих точок (REDEFINE-3 CV outcomes). Cagrilintide-моно ще не у Phase 3 — Novo сфокусована на CagriSema.
Часті запитання про Амілін (Cagrilintide)
Cagrilintide (Amilin 10 mg or 20 mg pre-mixed pen from PeptoLabs) can be ordered through DOZA with quality guarantee and 24/7 support. Delivery across Ukraine 1–2 days in thermal box (cold chain 2–8°C). 20 mg pen at standard maintenance dose 2.4 mg/week — lasts ~8–9 weeks. Before ordering — DOZA specialist consultation (protocol assessment: mono or combination with Mounjaro/Ozempic). Check exact price and pen quantity for course with consultant.
Спеціаліст DOZA
One Cagrilintide (Amilin) 20 mg pen — ₴16,400. Standard course 4–8 weeks. Course selection — free DOZA consultation.
Спеціаліст DOZA
Cagrilintide is an amylin hormone analog. Works through separate from GLP-1 pathway: suppresses appetite via area postrema, slows gastric emptying, reduces glucagon. Result — -10.8% weight in monotherapy and up to -22.7% combined with semaglutide (CagriSema).
Спеціаліст DOZA
Yes, this is Cagrilintide's key advantage. It works through amylin receptors (separate from GLP-1), so combines with Mounjaro (tirzepatide), Ozempic/Biopatid (semaglutide/tirzepatide) and Retatrutide. In clinical study (USA, T2D) combination cagrilintide 1.2 mg + semaglutide 1.2 mg gave -15.6% weight and -2.2% HbA1c — more than semaglutide 2.4 mg alone (-5.1% weight). Novo Nordisk developed CagriSema with -22.7% result in REDEFINE-2.
Спеціаліст DOZA
Standard 16-week titration (as in Novo Nordisk Phase 3 CagriSema): weeks 1–4 — 0.25 mg/week; weeks 5–8 — 0.5 mg; weeks 9–12 — 1.0 mg; weeks 13–16 — 1.7 mg; from week 17 — maintenance 2.4 mg/week. In clinical studies maximum — 4.5 mg/week (Phase 2 mono); in CagriSema — 2.4 mg/week. If combining with Mounjaro/Ozempic — start only after GLP-1 stabilization, otherwise risk of double GI side effects. Specific dose and titration schedule for your case calculated by DOZA specialist after assessing BMI, age, existing diagnoses and current therapy.
Спеціаліст DOZA
Cagrilintide is well tolerated. Most common: nausea (10–15%), decreased appetite (desired effect), constipation/diarrhea, slow digestion, abdominal heaviness. Mild-moderate, resolve spontaneously with adaptation.
Спеціаліст DOZA
Contraindications: medullary thyroid cancer (personal or family history), MEN-2, cagrilintide allergy, intestinal obstruction, frequent gastroesophageal reflux, pregnancy, lactation. DOZA specialist checks before prescribing.
Спеціаліст DOZA
People with excess weight (even without diabetes); in type 2 diabetes — before or together with GLP-1/GIP-GLP-1 agonists (Mounjaro, Ozempic, Biopatid, Retatrutide) for improved appetite and glucose control; in type 1 diabetes — as alternative when GLP-1 medications not suitable. Also reduces cardiovascular complication risk in diabetes and CVD.
Спеціаліст DOZA
Yes. In clinical study combination cagrilintide 1.2 mg + semaglutide 1.2 mg + metformin gave average HbA1c reduction of 2.2%, fasting glucose reduction of 3.3 mmol/L and weight loss of 15.6%. This is better result than semaglutide 2.4 mg monotherapy (-1.8% HbA1c, -5.1% weight).
Спеціаліст DOZA
CagriSema (cagrilintide 2.4 + semaglutide 2.4) in REDEFINE-1 (68 weeks) gave –22.7% weight loss. Mounjaro (tirzepatide) 15 mg in SURMOUNT-1 (72 weeks) — –20.9% weight loss. So by primary endpoint CagriSema slightly outperforms Mounjaro 15 mg (~+1.8 pp). However in December 2024 Novo Nordisk published data where CagriSema showed less effect than expected (~–22.7% instead of projected –25%) — shares fell 25% in one day. Mounjaro has advantage: already FDA/EMA approved (since 2022), available from 2025 in Ukraine; CagriSema — only research-grade until 2026–2027. Practical conclusion: for first attempts — Mounjaro/Ozempic; CagriSema for those who plateau on GLP-1.
Спеціаліст DOZA
Depends on duration and dose. 16-week starter titration course (0.25→2.4 mg/week) uses total ~27 mg = 3 pens of 10 mg or 1.5 pens of 20 mg. Then maintenance 2.4 mg/week: 20 mg pen — for 8–9 weeks, 10 mg pen — for 4 weeks. For full yearly course (52 weeks) at 2.4 mg/week need ~125 mg = 7 pens of 20 mg or 13 pens of 10 mg. Exact quantity and order schedule calculated by DOZA consultant after discussing goals (short-term push, long-term maintenance, GLP-1 combination).
Спеціаліст DOZA
Client reviews
Амілін (Cagrilintide) — felt the effect after the first week. Fast delivery, everything in thermo-packaging. DOZA — thank you for the support!
Ordering Амілін (Cagrilintide) for the second course already. Original quality, fair price. DOZA consultant answered all my questions.
Buy Амілін (Cagrilintide) in Ukraine — DOZA
Амілін (Cagrilintide) is available in Ukraine through DOZA online service. Amylin analog — a new pathway for appetite control. We ensure original quality, safe storage and delivery across Ukraine via Nova Poshta. Every order includes a free specialist consultation.
Price of Амілін (Cagrilintide) — 16 400 ₴. For detailed information about dosage, course and suitability, please consult a DOZA specialist.
Buy Амілін (Cagrilintide) with 1–2 day delivery across Ukraine. Cold chain 2–8°C. We respond 24/7.
Also recommended
Дивіться також
Амілін: гормон ситості, про який мовчать лікарі
Амілін: гормон ситості, про який мовчать лікарі
Три механізми схуднення: чому амілін працює інакше, ніж Mou…
Три механізми схуднення: чому амілін працює інакше, ніж Mounjaro та Ozempic
Нудота від кагрілінтіду минає за 4 тижні: повний гід по поб…
Нудота від кагрілінтіду минає за 4 тижні: повний гід по побічних ефектах амілін